Hirudoid

Hirudoid Cream

Heparinoid 0.3% wlw (Equivalent to 25 000 Units per 100 g cream).

Excipient(s) with known effect

For the full list of excipients, see section 6.1.

Topical cream.

Hirudoid is indicated for the treatment of superficial thrombophlebitis and the soothing relief of superficial bruising and haematoma.

Adults, the elderly and children over 5 years of age:

Two to six inches (5-15 cm) to be applied up to four times daily to the affected area and gently massaged into the skin.

Not to be used on large areas of skin, broken skin, sensitive areas of skin or mucous membranes. Not to be used in individuals with a known sensitivity to any active or inactive component of the formulation. Not to be used in children under 5 years of age.

For external use only. If symptoms persist or worsen, seek medical advice. Do not exceed the stated dose.

Instruct patients not to smoke or go near naked flames – risk of severe burns. Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard. Washing clothing and bedding may reduce product build-up but not totally remove it.

Ingredients with specified warnings

This product contains Cetostearyl alcohol and lanolin which may cause local skin reactions (e.g. contact dermatitis).

This product contains propyl parahydroxybenzoate and ethyl parahydroxybenzoate which may cause allergic reactions (possibly delayed).

None known.

There is no evidence to suggest that Hirudoid should not be used during pregnancy and lactation.

None.

None known.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for 'MHRA Yellow Card' in the Google Play or Apple App Store.

In the absence of any reports of the accidental ingestion of Hirudoid, no specific advice is available. General supportive measures may be appropriate.

Heparinoid is recognised as having: a weak inhibitory effect on PGE₂ synthesis and an indirect effect on LTB₄ production (based on in vitro studies), anti-coagulant activity (as a heparinoid), thrombolytic activity (through potentiation of urokinase activity), anti-exudatory activity (through inhibition of hyaluronidase).

Radiochemical studies of absorption following cutaneous application of heparinoid (mucopolysaccharide polysulphate) have shown that between 0.3 and 4% of the mucopolysaccharide administered is absorbed by various tissues (other than the treated area) within the first 8 hours. Typically between 1.7% and 4.6% will be absorbed within 2 to 4 days. Animal studies have also shown that mucopolysaccharide is bound intracellularly within the subcutis. Peak serum concentrations following cutaneous application are below the threshold of physiological relevance for coagulation. Mucopolysaccharide is excreted in the urine partly unchanged and partly as depolymerized, shorter chain length molecules.

None stated.

Anhydrous eucerine (contains lanolin)

Emulsifying cetostearyl alcohol type A

Glycerol

Isopropyl alcohol

Methyl parahydroxybenzoate (E218)

Myristyl alcohol

Potassium hydroxide

Propyl parahydroxybenzoate (E216)

Purified water

Stearic acid

Thymol

None.

5 years.

Store below 25°C.

Lacquered aluminium tubes 14, 40, 50g.

Not applicable.

Thornton & Ross Ltd.

Linthwaite,

Huddersfield,

HD7 5QH, UK

PL 00240/0556

02/02/2006

15/11/2023